Spyre Therapeutics will report topline results for SPY001 in ulcerative colitis on April 13, 2026, followed by a conference call.
Quiver AI Summary
Spyre Therapeutics, Inc. has announced that it will release topline results from the SPY001 Part A induction phase of the SKYLINE trial for moderate-to-severely active ulcerative colitis patients on April 13, 2026. The company focuses on developing long-acting antibodies and antibody combinations to improve treatment for inflammatory bowel disease and rheumatic diseases. Following the announcement of the results, Spyre will hold a conference call and webcast at 8:00 am ET on the same day to discuss the findings. The details for accessing the webcast can be found on the Investor Relations section of Spyre's website.
Potential Positives
- Spyre Therapeutics is set to announce topline results from the SKYLINE trial, a significant milestone that could impact treatment options for patients with moderate-to-severely active ulcerative colitis.
- The conference call and webcast following the announcement demonstrates transparency and a proactive approach in communicating with investors and the public.
Potential Negatives
- The announcement of the topline results indicates that the company is still in a clinical stage, which may raise concerns about its ability to deliver effective treatments in a timely manner.
- Potential high expectations from investors and stakeholders may be set for the upcoming results, creating pressure that could lead to negative reactions if the outcomes are not favorable.
- Being a clinical-stage company, Spyre Therapeutics faces inherent risks related to regulatory approvals and market acceptance, which could impact its financial stability.
FAQ
What are the topline results being reported by Spyre Therapeutics?
Spyre Therapeutics will report topline results from the SPY001 Part A induction phase of the SKYLINE trial for ulcerative colitis patients.
When will Spyre Therapeutics announce the results?
The topline results will be announced on Monday, April 13, 2026.
How can I access the conference call about the results?
The conference call and webcast will be accessible via the Investor Relations page on Spyre's website.
What types of diseases does Spyre Therapeutics focus on?
Spyre Therapeutics focuses on inflammatory bowel disease (IBD) and rheumatic diseases with its innovative antibody therapies.
Who can I contact for more information about Spyre Therapeutics?
For investor inquiries, contact Eric McIntyre, and for media inquiries, contact Josie Butler via their respective emails.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$SYRE Insider Trading Activity
$SYRE insiders have traded $SYRE stock on the open market 18 times in the past 6 months. Of those trades, 0 have been purchases and 18 have been sales.
Here’s a breakdown of recent trading of $SYRE stock by insiders over the last 6 months:
- CAMERON TURTLE (Chief Executive Officer) has made 0 purchases and 13 sales selling 120,000 shares for an estimated $3,810,090.
- SCOTT L BURROWS (Chief Financial Officer) has made 0 purchases and 4 sales selling 10,000 shares for an estimated $471,696.
- SHELDON SLOAN (Chief Medical Officer) sold 7,958 shares for an estimated $397,900
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$SYRE Hedge Fund Activity
We have seen 103 institutional investors add shares of $SYRE stock to their portfolio, and 42 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- FMR LLC added 2,578,675 shares (+28.5%) to their portfolio in Q4 2025, for an estimated $84,477,393
- PERCEPTIVE ADVISORS LLC added 1,839,780 shares (+149.6%) to their portfolio in Q4 2025, for an estimated $60,271,192
- JANUS HENDERSON GROUP PLC added 1,816,009 shares (+13969.3%) to their portfolio in Q4 2025, for an estimated $59,492,454
- RA CAPITAL MANAGEMENT, L.P. added 1,621,620 shares (+inf%) to their portfolio in Q4 2025, for an estimated $53,124,271
- BLACKROCK, INC. added 1,539,357 shares (+38.7%) to their portfolio in Q4 2025, for an estimated $50,429,335
- JEFFERIES FINANCIAL GROUP INC. removed 1,388,854 shares (-100.0%) from their portfolio in Q4 2025, for an estimated $45,498,857
- TANG CAPITAL MANAGEMENT LLC removed 1,307,800 shares (-40.9%) from their portfolio in Q4 2025, for an estimated $42,843,528
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$SYRE Analyst Ratings
Wall Street analysts have issued reports on $SYRE in the last several months. We have seen 2 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Mizuho issued a "Outperform" rating on 12/18/2025
- Jones Trading issued a "Buy" rating on 12/01/2025
To track analyst ratings and price targets for $SYRE, check out Quiver Quantitative's $SYRE forecast page.
$SYRE Price Targets
Multiple analysts have issued price targets for $SYRE recently. We have seen 6 analysts offer price targets for $SYRE in the last 6 months, with a median target of $64.0.
Here are some recent targets:
- Julian Harrison from BTIG set a target price of $70.0 on 03/31/2026
- Alex Thompson from Stifel set a target price of $92.0 on 03/18/2026
- Yanan Zhu from Wells Fargo set a target price of $50.0 on 02/20/2026
- Joseph Catanzaro from Mizuho set a target price of $53.0 on 12/18/2025
- Samantha Semenkow from Citigroup set a target price of $64.0 on 12/17/2025
- Debanjana Chatterjee from Jones Trading set a target price of $64.0 on 12/01/2025
Full Release
WALTHAM, Mass., April 10, 2026 (GLOBE NEWSWIRE) -- Spyre Therapeutics, Inc. (NASDAQ: SYRE), a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases, today announced it will report SPY001 Part A induction topline results from the SKYLINE trial in moderate-to-severely active ulcerative colitis patients on Monday, April 13, 2026. Following the announcement, the Company will host a conference call and webcast at 8:00am ET on Monday April 13, 2026 to discuss the results.
To access the live and archived webcast, please visit the Investor Relations page of Spyre’s website at https://ir.spyre.com/events-and-presentations .
About Spyre Therapeutics
Spyre Therapeutics is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (“IBD”) and rheumatic diseases. Spyre's pipeline includes investigational extended half-life antibodies targeting α4β7, TL1A, and IL-23.
For more information, visit Spyre's website at www.spyre.com .
For Investors:
Eric McIntyre, Spyre Therapeutics
SVP of Finance and Investor Relations
[email protected]
For Media:
Josie Butler, 1AB
[email protected]
